Abstract: OBJECTIVE To analyze the cost-effectiveness of doxorubicin/cyclophosphamide/paclitaxel/trastuzumab (AC-TH) and docetaxel/carboplatin/trastuzumab(TCH). METHODS A Markov model was built to simulate the process of breast cancer events and death occurred in both AC-TH and TCH armed patients and to choose a suitable chemotherapy method. Data were collected from the clinical trials, some publicized literatures and patients' diaries of a large Chinese comprehensive hospital. The cost-effectiveness analysis of two regimens and sensitivity analysis were performed using a Markov model. RESULTS The 5 years' results showed that patients receiving TCH gained 3.6 (quality-adjusted life years, QALYs) which were 0.2 QALYs more than patients receiving AC-TH. The ICER value was -229700 Yuan/QALY. The costs of patients receiving AC-TH were 207 987 Yuan which were 45 940 Yuan more than that of TCH. CONCLUSION Compared with AC-TH regimen, TCH can be viewed as cost-effective for breast cancer patients in 5 years horizon from a Chinese health system perspective.